Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib, zanubrutinib, ibrutinib, and its active meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lu-Ning, Zhao, Yang, Qian, Zhou-Yi, Chen, Xiang-Long, Ma, Hong, Guo, Yu-Jiao, Shen, Hao, Wang, Yong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920560/
https://www.ncbi.nlm.nih.gov/pubmed/36770870
http://dx.doi.org/10.3390/molecules28031205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920560/
https://www.ncbi.nlm.nih.gov/pubmed/36770870
http://dx.doi.org/10.3390/molecules28031205

Ejemplares similares